http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014505107-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 |
| filingDate | 2012-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2014505107-A |
| titleOfInvention | Methods for inhibiting hamartoma tumor cells |
| abstract | Dimorpholinopyrimidines are useful for inhibiting the growth or proliferation of hamartoma tumor cells. Since dimorpholinopyrimidines inhibit the growth or proliferation of hamartoma tumor cells, they are also useful for treating PTEN hamartoma tumor syndrome. The therapeutic and prophylactic treatment provided by the present invention is performed by administering to a patient in need thereof a compound that is a dimorpholinopyrimidine derivative in an amount effective to inhibit the growth or proliferation of hamartoma tumor cells. Is done. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017513888-A |
| priorityDate | 2011-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 241.